All In Biotech

Drug Trial Radar · NCT06975722

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of Brivekimig in Adult Participants With Moderate to Severe Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

105

Actual

Start

Jul 7, 2025

Primary completion

Dec 17, 2026

Study completion Oct 17, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Conditions

  • Ulcerative Colitis

Interventions

  • SAR442970Drug

    Route of administration: Subcutaneous

  • PlaceboDrug

    Route of administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS)Time frame: At Week 16

Locations

61 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigational Site Number: 8400027

    Fairhope, Alabama

  • Investigational Site Number: 8400009

    Escondido, California

  • Investigational Site Number: 8400006

    Lancaster, California

  • Investigational Site Number: 8400025

    Thousand Oaks, California

  • Investigational Site Number: 8400024

    Jacksonville, Florida

  • Investigational Site Number: 8400003

    Lighthouse PT, Florida

  • Investigational Site Number: 8400001

    Miami, Florida

  • Investigational Site Number: 8400011

    Miami, Florida

  • Investigational Site Number: 8400010

    Palmetto Bay, Florida

  • Investigational Site Number: 8400019

    Tampa, Florida

  • Investigational Site Number: 8400018

    Marietta, Georgia

  • Investigational Site Number: 8400005

    Iowa City, Iowa

  • Investigational Site Number: 8400017

    Boston, Massachusetts

  • Investigational Site Number: 8400014

    St Louis, Missouri

  • Investigational Site Number: 8400029

    Queens Village, New York

  • Investigational Site Number: 8400023

    Houston, Texas

  • Investigational Site Number: 8400007

    Ogden, Utah

  • Investigational Site Number: 0360001

    Clayton, Victoria, Australia

  • Investigational Site Number: 1560001

    Hangzhou, China

  • Investigational Site Number: 1560007

    Ningbo, China

  • Investigational Site Number: 1560004

    Huizhou, Ghangdong, China

  • Investigational Site Number: 1560005

    Guangzhou, Guangdong, China

  • Investigational Site Number: 1560002

    Nanjing, Jiangsu, China

  • Investigational Site Number: 1560008

    Suzhou, Jiangsu, China

  • Investigational Site Number: 1560003

    Wuxi, Jiangsu, China

  • Investigational Site Number: 1560009

    Shanghai, Shanghai Municipality, China

  • Investigational Site Number: 2030001

    Brno, JM, Czechia

  • Investigational Site Number: 2500002

    Lille, France

  • Investigational Site Number: 2500007

    Montpellier, France

  • Investigational Site Number: 2500006

    Nice, France

  • Investigational Site Number: 2500005

    Pierre-Bénite, France

  • Investigational Site Number: 2500001

    Saint-Priest-en-Jarez, France

  • Investigational Site Number: 2760001

    Minden, Northwest, Germany

  • Investigational Site Number: 2760005

    Kiel, Schleswig-Holstein, Germany

  • Investigational Site Number: 3480003

    Budapest, Hungary

  • Investigational Site Number: 3480002

    Budapest, Hungary

  • Investigational Site Number: 3480001

    Vác, Hungary

  • Investigational Site Number: 3920005

    Hamamatsu, Japan

  • Investigational Site Number: 3920003

    Hirosaki, Japan

  • Investigational Site Number: 3920001

    Morioka, Japan

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.